Business Context and Reporting Period
This Form 8-K Current Report was filed by Novavax, Inc. on August 16, 2021. The filing primarily addresses Item 5.02 regarding the appointment of a new Chief Financial Officer and the transition of the interim CFO.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive compensation and personnel changes.
Material Changes
The material change reported is the appointment of James P. Kelly as Executive Vice President, Chief Financial Officer, and Treasurer, effective August 16, 2021. Concurrently, John J. Trizzino transitioned from his role as Interim Chief Financial Officer to continue serving as Executive Vice President, Chief Commercial Officer, and Chief Business Officer.
Compensation and Employment Terms
- Base Salary: $490,000 annually.
- Target Bonus: 45% of base salary, payable in cash, stock options, or restricted stock.
- Signing Bonus: One-time payment of $100,000, subject to pro-rated repayment if employment ends before 24 months.
- Equity Grants:
- 14,200 stock options (25% vesting on first anniversary, remainder monthly over 36 months).
- 7,100 restricted stock units (vesting annually over three years).
- Severance: In the event of termination without cause or resignation for good reason, Mr. Kelly is entitled to 12 months of salary plus 12 months of COBRA premiums.
- Restrictions: Includes a 12-month non-compete and non-solicitation covenant following termination.
Investor Verification Checklist
- Verify the full text of the Offer Letter and Employment Agreement in the upcoming Form 10-Q for the quarter ended September 30, 2021.
- Confirm the vesting schedules and performance goals associated with the target bonus and equity grants.
- Review the press release (Exhibit 99.1) for additional leadership updates mentioned in the filing.
- Monitor future filings for any changes to the company's financial strategy under the new CFO leadership.